Publications by authors named "D Arıkan"
Objective: An unmet need exists for glucocorticoid-sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody-drug conjugate ABBV-154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV-154 versus placebo in patients with glucocorticoid-dependent PMR.
View Article and Find Full Text PDFArticle Synopsis
- This study examines the relationship between fetal clavicle length and gestational age in pregnant women between 14 and 27 weeks.
- Measurements of various fetal dimensions, like clavicle length and abdominal circumference, were taken through ultrasound and showed strong correlations with gestational age.
- The findings indicate a significant positive correlation between clavicle length and gestational week, suggesting a rule where 1 mm of clavicle length corresponds to 1 week of gestation, particularly useful for certain patient conditions.
Article Synopsis
- ABBV-3373 is an antibody-drug conjugate that combines adalimumab with a glucocorticoid receptor modulator, aimed at treating immune-mediated inflammatory diseases, and its first human study assessed its safety, pharmacokinetics, and immunogenicity in healthy participants.
- The study involved 55 participants receiving different doses of ABBV-3373 via subcutaneous or intravenous routes, with blood samples collected to analyze drug behavior and immune response over 85 days.
- Results showed that ABBV-3373 had favorable drug profiles and was mostly well-tolerated, with mild side effects noted, while not significantly affecting serum cortisol levels, supporting its further clinical development.*
Article Synopsis
- The study evaluated the effectiveness and safety of ABBV-3373, an antibody-drug conjugate combining adalimumab with a glucocorticoid receptor modulator, in treating rheumatoid arthritis compared to standard adalimumab.
- In a randomized trial with 48 patients, those receiving ABBV-3373 showed significant improvement in disease activity scores (DAS28-CRP) at week 12 compared to historical data for adalimumab.
- ABBV-3373 also demonstrated promising secondary outcomes, suggesting it may be more effective than adalimumab with a high probability of superiority in treating patients with moderate-to-severe RA.
Background: Fatty liver index (FLI) is a simple tool used to predict non-alcoholic fatty liver disease (NAFLD). The role of FLI in polycystic ovary syndrome (PCOS) for the prediction of NAFLD has not been elucidated.
Methods: This case-control study was from January 2014 to January 2016.